Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment

Transplantation

Volumn 75, Issue 7, 2003, Pages 987-993

  Guthery, Stephen L ^a,c   Heubi, James E ^a   Bucuvalas, John C ^a   Gross, Thomas G ^a   Ryckman, Frederick C ^a   Alonso, Maria H ^a   Balistreri, William F ^a   Hornung, Richard W ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; DACLIZUMAB; MYCOPHENOLIC ACID; OKT 3; RAPAMYCIN; TACROLIMUS;

AGE; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE CLASSIFICATION; EPSTEIN BARR VIRUS; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; NEOPLASM; NEWBORN; NONBIOLOGICAL MODEL; NONHUMAN; PEDIATRICS; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL RATE;

EID: 0037446832     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000057244.03192.BD     Document Type: Article

References (18)

1. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995; 59(4): 524.
2. Newell KA, Alonso EM, Whitington PF, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 1996; 62(3): 370.
3. Younes BS, McDiarmid SV, Martin MG, et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation 2000; 70(1): 94.
4. Cacciarelli TV, Reyes J, Jaffe R, et al. Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients. Pediatr Transplant 2001; 5(5): 359.
5. Sokal EM, Antunes H, Beguin C, et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation 1997; 64(10): 1438.
6. Molmenti EP, Nagata DE, Roden JS, et al. Post-transplant lymphoproliferative syndrome in the pediatric liver transplant population. Am J Transplant 2002; 1(4): 356.
7. Jain A, Mazariegos GV, Kashyap RS, et al. Comparison of post transplant lymphoproliferative disorders (PTLD) under cyclosporine and tacrolimus, 766 consecutive recipients: 15 years experience. Am J Transplant 2001; 1(1): 235A.
8. Swerdlow AJ, Higgins CD, Hunt BJ, et al. Risk of lymphoid neoplasia after cardiothoracic transplantation, a cohort study of the relation to Epstein-Barr virus. Transplantation 2000; 69(5): 897.
9. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323(25): 1723.
10. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced post-transplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68(10): 1517.
11. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U. S. Multicenter FK506 Liver Study Group. N Engl J Med 1994; 331(17): 1110.
12. Weiss LM, Chen YY, Liu XF, et al. Epstein-Barr virus and Hodgkin's disease. A correlative in situ hybridization and polymerase chain reaction study. Am J Pathol 1991; 139(6): 1259.
13. Chang KL, Chen YY, Shibata D, et al. Description of an in situ hybridization methodology for detection of Epstein-Barr virus RNA in paraffin-embedded tissues, with a survey of normal and neoplastic tissues. Diagn Mol Pathol 1992; 1(4): 246.
14. Dror Y, Greenberg M, Taylor G, et al. Lymphoproliferative disorders after organ transplantation in children. Transplantation 1999; 67(7): 990.
15. Peters DH, Fitton A, Plosker GL, et al. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993; 46(4): 746.
16. [No authors listed.] Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet 1994; 344(8920): 423.
17. Straus SE, Cohen JI, Tosato G, et al. NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med 1993; 118(1): 45.
18. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33(1): 159.